GleamWall
中文EN

QGEN QIAGEN N.V.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1015820 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.7%
TTM net income YoY408.3%
TTM EPS YoY424.3%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR0.1%

Margins

Gross margin62.2%
Operating margin22.3%
Net margin20.3%
FCF margin21.7%
EBITDA margin31.6%

Returns

ROE11.6%
ROA7.1%
ROIC (approx.)9.1%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets39.9%
Debt / equity0.44x
Current ratio3.90x
Interest coverage14.01x

Cash quality & payout

Operating cash flow / net income1.54x
Accruals ratio-3.8%
Payout ratio12.8%
Capex / revenue9.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-30
Income statement
Revenue—
Net income—
EPS (diluted)—
Dividends declared per share0.25
Balance sheet
Total assets—
Shareholders' equity—
Cash flow statement
Operating cash flow—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.